Joel Simrén

Nov 14, 2024 | bpspsychub.onlinelibrary.wiley.com | Joel Simrén |Nicholas Ashton |Marc Suárez-Calvet |Henrik Zetterberg

Recent developments in fluid and imaging biomarkers that reflect the key pathological hallmarks of Alzheimer's disease (AD)—deposits of extracellular amyloid-β (Aβ) and intracellular tau proteins—have transformed the perception of the disease in living individuals from a clinical syndrome to a biological continuum that begins prior to the onset of symptoms (Scheltens et al., 2021).

Nov 20, 2023 | alz-journals.onlinelibrary.wiley.com | Wagner S. Brum |Nicholas Ashton |Joel Simrén

1 BACKGROUND Novel technologies to measure brain pathophysiological processes in the blood have revolutionized the Alzheimer's disease (AD) research landscape.1, 2 Established and highly accurate methods for tracking such processes face barriers to their large-scale implementation, such as the high costs, radiation exposure, and limited availability of positron emission tomography (PET) scans, as well as the relative invasiveness of lumbar punctures, required for measuring AD biomarkers in...